RxDoctor Payments DataLook up a doctor →

Vijaykumar Kasi, MD

Interventional Cardiology · Orlando, FLNPI 1235334301

Payments from drug & device makers

$1,094,989in general payments, 2019–2025

Across 458 payments — averaging $2390.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$770K
  • Abbott$132K
  • Arrow International, Inc.$53K
  • Novo Nordisk$47K
  • Amgen$38K
  • Stryker$15K
  • plus $40K from 25 others

What the payments were for

  • Consulting fees$6,4388%
  • Speaking & faculty fees$53,36269%
  • Travel & lodging$6,1468%
  • Food & beverage$11,18814%
  • Education$1000%
  • Gifts$2050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,094,989 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$198,225
Medicare patients
1,039
Services billed
2,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban271$322,461
OzempicSemaglutide63$63,864
BrilintaTicagrelor72$56,819
FarxigaDapagliflozin Propanediol47$34,043
Repatha SureclickEvolocumab33$33,344
XareltoRivaroxaban17$24,698
WegovySemaglutide15$19,802
MounjaroTirzepatide15$16,084
Praluent PenAlirocumab20$13,657
Prasugrel Hcl20$5,357
Ezetimibe199$3,160
Ranolazine ErRanolazine28$2,732
ClopidogrelClopidogrel Bisulfate274$2,614
Atorvastatin Calcium235$1,877
Rosuvastatin Calcium124$1,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$322,461271 claims
AstraZenecaBrilinta, Farxiga$5,802$90,861119 claims
Novo NordiskOzempic, Wegovy$46,554$83,66678 claims
Lilly USA, LLCMounjaro$64$16,08415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →